We can't find the internet
Attempting to reconnect
Something went wrong!
Hang in there while we get back on track
Spore-Forming Probiotic-Embedded Biomaterials for Targeted Gut Microplastic Biodegradation
Summary
The tiny plastic particles we accidentally eat can build up in our gut, damaging its protective lining and disrupting healthy bacteria. This paper proposes (but doesn't yet test in humans) a possible fix: packaging special hardy probiotic bacteria—ones that can survive stomach acid and break down plastic—into protective capsules or gels that could release them right where microplastics collect in the gut. It's an early-stage concept for future "living pill" treatments, not a proven therapy yet, but it points toward a promising way to help our bodies clear out unwanted plastic.
Microplastic (MP) exposure compromises gut barrier integrity, microbial homeostasis, and host immunity to accelerate mucosal dysfunction and disease progression. This necessitates new strategies to address gut MP accumulation concerns. Unlike environmental settings, the gut imposes harsh physiological constraints that restrict conventional plastic biodegradation mechanism feasibility. Spore-forming probiotic (SFP) strains possess intrinsic resilience and diverse plastic degradation metabolic capacities enzymatic, biosurfactant-mediated, and oxidative pathways; however, their functional deployment is limited by spatial dilution, enzyme instability, and insufficient polymer-microbe contact. This perspective presents SFP-integrated biomaterial platforms as a conceptual framework for enabling controlled gut microbe-MP interactions. Specifically, we discuss how embedding SFPs into engineered microcapsule, hydrogel, and polymer film biomaterials to localize probiotic activity, regulate germination and secretion dynamics, and mediate controlled MP interactions within gut-physiological conditions. We further outline the mechanistic basis of SFP-mediated MP biodegradation and biomaterial design strategies for optimized targeted activity to create future SFP-assisted gut MP therapeutics.